Dr. Ariella Hanker (@ariellahanker) 's Twitter Profile
Dr. Ariella Hanker

@ariellahanker

Assistant Professor @UTSWcancer and mom of 3. Researching resistance to #BreastCancer targeted therapies. #celiacdisease patient and pasta lover. Tweets my own.

ID: 2330640865

linkhttps://profiles.utsouthwestern.edu/profile/179679/ariella-hanker.html calendar_today06-02-2014 17:50:29

2,2K Tweet

2,2K Followers

1,1K Following

Cancer Discovery (@cd_aacr) 's Twitter Profile Photo

Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker Andrew Aguirre: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw

Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker <a href="/andrewaguirremd/">Andrew Aguirre</a>: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw
AACR (@aacr) 's Twitter Profile Photo

At yesterday's opening ceremony, we asked the cancer community to stand together to make their voices heard in support of innovative cancer science and medicine. #CancerResearchSavesLives® #AACR25

Ingo Hartung (@hartungingo) 's Twitter Profile Photo

Frank McCormick in the Ras townhall at #AACR25 introducing BridgeBio‘s Ras-PI3K complex breaker BBO-10203. Derived from an insulin function mimetic glue by structure-based design. Yet another facette of modulating Ras biology with small molecules. Who called Ras „undruggable“? 😆

Frank McCormick in the Ras townhall at #AACR25 introducing BridgeBio‘s Ras-PI3K complex breaker BBO-10203. Derived from an insulin function mimetic glue by structure-based design. Yet another facette of modulating Ras biology with small molecules. Who called Ras „undruggable“? 😆
Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

New work from ⁦Sandra Misale⁩ and team: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations | Cancer Discovery | American Association for Cancer Research | #AACR25 aacrjournals.org/cancerdiscover…

Dr. Ariella Hanker (@ariellahanker) 's Twitter Profile Photo

Hey #AACR25, is there a role for CDK inhibitors in the context of #RB1 loss? Check out Dr. Albert Lin’s poster on targeting #CDK2 in this context! Tomorrow (Tuesday) at 2 pm UTSW Simmons Cancer Center

Hey #AACR25, is there a role for CDK inhibitors in the context of #RB1 loss? Check out Dr. Albert Lin’s poster on targeting #CDK2 in this context! Tomorrow (Tuesday) at 2 pm <a href="/utswcancer/">UTSW Simmons Cancer Center</a>
Dr. Ariella Hanker (@ariellahanker) 's Twitter Profile Photo

Impressive responses to #HER2-selective TKI #zongertinib in HER2mut #NSCLC, with ⬇️ diarrhea and rash ➡️what about other tumor types driven by HER2 mutations, like breast? ➡️what are the mechanisms of resistance? On target secondary HER2 mutations? #AACR25 nejm.org/doi/full/10.10…

Sandra Misale (@sandra_misale) 's Twitter Profile Photo

Fresh out of press! 🧬🔬We are happy to share our latest work published in Diana Hoffman! shorturl.at/F4qnr A thread🧵 Please, Enjoy and share! #CancerResearch, #PrecisionOncology #CancerTherapeutics

Dr. Ariella Hanker (@ariellahanker) 's Twitter Profile Photo

Next up at #AACR25 #SABCS24 session: Brooke Felsheim UNC Lineberger defines prognostic features in #TNBC using DNA+RNA. #Bcells + #Tcells, RNA signature prognostic. #HRDscore not predictive nature.com/articles/s4152… npj Journals

Next up at #AACR25 #SABCS24 session: Brooke Felsheim <a href="/UNC_Lineberger/">UNC Lineberger</a> defines prognostic features in #TNBC using DNA+RNA. #Bcells + #Tcells, RNA signature prognostic. #HRDscore not predictive 
nature.com/articles/s4152… <a href="/Nature_NPJ/">npj Journals</a>
Lowe Lab (@lowelabmskcc) 's Twitter Profile Photo

Out now in Cancer Discovery and featured #AACR25, we show a combinatorial approach to overcome resistance to RAS(ON) inhibitor monotherapy in PDAC, where use of CDK4/6 inhibitor Palbociclib and CD40 agonist drives therapy-induced senescence & CD4 T cell-dependent tumor-immune equilibrium

Neil Vasan (@neilvasan) 's Twitter Profile Photo

I am thrilled to have joined NYU Langone Health Perlmutter Cancer Center at NYU Langone Health on May 1, 2025 as Assistant Professor and Director of Translational Research in Breast Cancer. Excited to launch the next chapter of our lab’s work in NYC and accelerate impact for patients with breast cancer.